Abstract.
Liver X receptors (LXRs) α and β are nuclear oxysterol receptors and metabolic sensors initially found to regulate cholesterol metabolism and lipid biosynthesis. Recent studies have elucidated the importance of LXR in the development of cardiovascular diseases and metabolic disorders. LXR agonists prevent development of atherosclerosis by modulation of metabolic as well as inflammatory gene expression in rodent models. Moreover, LXR activation inhibits hepatic gluconeogenesis and lowers serum glucose levels, indicating possible application of LXR activation in the treatment of diabetes mellitus. However, first-generation LXR agonists elevate hepatic and serum trigylceride levels, making subtype-specific agonists and selective LXR modulators rather than unselective LXR agonists a potential pharmacological strategy. This review summarizes the multiple physiological and pathophysiological implications of LXRs and observations that identify LXRs as potential targets for therapeutic interventions in human cardiovascular and metabolic disease.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 30 August 2005; received after revision 10 October 2005; accepted 4 November 2005
Rights and permissions
About this article
Cite this article
Geyeregger, R., Zeyda, M. & Stulnig, T.M. Liver X receptors in cardiovascular and metabolic disease. Cell. Mol. Life Sci. 63, 524 (2006). https://doi.org/10.1007/s00018-005-5398-3
Published:
DOI: https://doi.org/10.1007/s00018-005-5398-3